These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 20375664)

  • 21. End-points and clinical trial design in pulmonary arterial hypertension: have we made progress?
    Peacock AJ; Naeije R; Galiè N; Rubin L
    Eur Respir J; 2009 Jul; 34(1):231-42. PubMed ID: 19567606
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of oral treatments on exercise capacity in systemic sclerosis related pulmonary arterial hypertension: a meta-analysis of randomised controlled trials.
    Avouac J; Wipff J; Kahan A; Allanore Y
    Ann Rheum Dis; 2008 Jun; 67(6):808-14. PubMed ID: 17901091
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endpoints in PAH clinical trials in the era of combination therapy: how do we decide whether something is working without going bankrupt?
    McGlinchey N; Peacock AJ
    Drug Discov Today; 2014 Aug; 19(8):1236-40. PubMed ID: 24814434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The changing paradigm in pulmonary hypertension trials: longer duration, new endpoints.
    LeVarge BL; Channick RN
    Curr Opin Pulm Med; 2015 Sep; 21(5):438-45. PubMed ID: 26176969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New perspectives in long-term outcomes in clinical trials of pulmonary arterial hypertension.
    Preston IR; Suissa S; Humbert M
    Eur Respir Rev; 2013 Dec; 22(130):495-502. PubMed ID: 24293465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical perspective: biomarkers in pulmonary arterial hypertension.
    Heresi GA
    Int J Clin Pract Suppl; 2011 Jan; (169):5-7. PubMed ID: 21176009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials.
    du Bois RM; Nathan SD; Richeldi L; Schwarz MI; Noble PW
    Am J Respir Crit Care Med; 2012 Oct; 186(8):712-5. PubMed ID: 22798316
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Traditional and alternative designs for pulmonary arterial hypertension trials.
    Gomberg-Maitland M
    Proc Am Thorac Soc; 2008 Jul; 5(5):610-6. PubMed ID: 18625753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk assessment tools for survival prognosis: An era of new surrogacy endpoints for clinical outcome measurement in pulmonary arterial hypertension clinical trials?
    Sanna L; Todea A
    Respir Med Res; 2022 May; 81():100893. PubMed ID: 35523041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Future of clinical trials for pulmonary hypertension.
    Rich S
    Circulation; 2011 Jun; 123(25):2919-21. PubMed ID: 21709071
    [No Abstract]   [Full Text] [Related]  

  • 31. New trial designs and potential therapies for pulmonary artery hypertension.
    Gomberg-Maitland M; Bull TM; Saggar R; Barst RJ; Elgazayerly A; Fleming TR; Grimminger F; Rainisio M; Stewart DJ; Stockbridge N; Ventura C; Ghofrani AH; Rubin LJ
    J Am Coll Cardiol; 2013 Dec; 62(25 Suppl):D82-91. PubMed ID: 24355645
    [TBL] [Abstract][Full Text] [Related]  

  • 32. End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives.
    Hoeper MM; Oudiz RJ; Peacock A; Tapson VF; Haworth SG; Frost AE; Torbicki A
    J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):48S-55S. PubMed ID: 15194178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evolution and optimization of clinical trial endpoints and design in pulmonary arterial hypertension.
    Caccamo M; Harrell FE; Hemnes AR
    Pulm Circ; 2023 Jul; 13(3):e12271. PubMed ID: 37554146
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pulmonary hypertension trials: how can we do better?
    Hill NS; Roberts K; Preston I
    Expert Rev Respir Med; 2015 Oct; 9(5):551-8. PubMed ID: 26290120
    [TBL] [Abstract][Full Text] [Related]  

  • 35. End points and clinical trial design in pulmonary arterial hypertension.
    McLaughlin VV; Badesch DB; Delcroix M; Fleming TR; Gaine SP; Galiè N; Gibbs JSR; Kim NH; Oudiz RJ; Peacock A; Provencher S; Sitbon O; Tapson VF; Seeger W
    J Am Coll Cardiol; 2009 Jun; 54(1 Suppl):S97-S107. PubMed ID: 19555863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physicians' and patients' expectations of therapies for pulmonary arterial hypertension: where do they meet?
    Howard LS; Ferrari P; Mehta S
    Eur Respir Rev; 2014 Dec; 23(134):458-68. PubMed ID: 25445944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The evolving landscape of pulmonary arterial hypertension clinical trials.
    Weatherald J; Boucly A; Peters A; Montani D; Prasad K; Psotka MA; Zannad F; Gomberg-Maitland M; McLaughlin V; Simonneau G; Humbert M;
    Lancet; 2022 Nov; 400(10366):1884-1898. PubMed ID: 36436527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trial research in focus: improving drug development and trial design in pulmonary arterial hypertension.
    Lajoie AC; Bonnet S; Provencher S
    Lancet Respir Med; 2017 Jul; 5(7):544-546. PubMed ID: 28664855
    [No Abstract]   [Full Text] [Related]  

  • 39. [New trial designs and potential therapies for pulmonary artery hypertension].
    Gomberg-Maitland M; Bull TM; Saggar R; Barst RJ; Elgazayerly A; Fleming TR; Grimminger F; Rainisio M; Stewart DJ; Stockbridge N; Ventura C; Ghofrani AH; Rubin LJ
    Turk Kardiyol Dern Ars; 2014 Oct; 42 Suppl 1():106-18. PubMed ID: 25697038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Updating clinical endpoint definitions.
    Hassoun PM; Nikkho S; Rosenzweig EB; Moreschi G; Lawrence J; Teeter J; Meier C; Ghofrani AH; Minai O; Rinaldi P; Michelakis E; Oudiz RJ
    Pulm Circ; 2013 Jan; 3(1):206-16. PubMed ID: 23662199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.